|
Title
|
|
|
|
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Introduction: Molecular alterations in neurotrophic tyrosine kinase (NTRK) genes have been identified in several solid tumors including lung cancer. Pre-clinical and clinical evidence suggested their potential role as oncogenic drivers and predictive biomarkers for targeted inhibition, leading to the clinical development of a new class of compounds blocking the NTRK molecular pathway, which are currently undner early clinical investigation. Area covered: This review describes the biology of the NTRK pathway and its molecular alterations in lung cancer. It focuses on the pre-clinical and clinical development of emerging NTRK inhibitors, which have shown very promising activity in early phase I studies. Expert opinion: Among the several NTRK-inhibitors, entrectinib and LOXO-101 are those in more advanced stage of clinical development. Both agents have shown encouraging activity along with a tolerable safety profile in patients with different solid tumors harboring NTRK-fusions, emerging as new promising therapeutic options for molecularly selected patients with advanced Trk-driven lung cancers. Results from ongoing phase II basket trials are eagerly awaited. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Expert opinion on investigational drugs. - London
|
|
|
Publication
|
|
|
|
Abingdon
:
Taylor & francis ltd
,
2016
|
|
|
ISSN
|
|
|
|
1354-3784
|
|
|
DOI
|
|
|
|
10.1517/13543784.2016.1152261
|
|
|
Volume/pages
|
|
|
|
25
:4
(2016)
, p. 385-392
|
|
|
ISI
|
|
|
|
000372076200003
|
|
|
Pubmed ID
|
|
|
|
26881293
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|